-
公开(公告)号：US20240100202A1
公开(公告)日：2024-03-28
申请号：US18261901
申请日：2022-01-17
申请人： ORANO MED
发明人： Amal Saidi , Amy Wong , Julien Torgue , Tania Stallons
CPC分类号： A61K51/0497 , A61P35/00
摘要： A PSMA-targeting conjugate or a pharmaceutically acceptable salt which may be used either for preparing a radiopharmaceutical or, once labeled with a radionuclide, as a radiopharmaceutical. The conjugate is of formula (I): A1-L1-Ch-L2-A2 (I) wherein: Ch is a chelator, L1 and L2, identical or different, are a linker whereas A1 and A2, identical or different, are a urea-based PSMA ligand.
-
公开(公告)号：US20220031871A1
公开(公告)日：2022-02-03
申请号：US17048072
申请日：2019-04-16
发明人： Julien TORGUE , Paul JUREK , Federico ROJAS-QUIJANO , Garry E. KIEFER , Olivier FREYTAG , Christian GERDES , Christian KLEIN , Pablo UMANA , Alexander HAAS , Sofia FROST , Amal SAIDI , Tapan NAYAK
摘要： The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies, It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and useful in such methods.
-
公开(公告)号：US20220013246A1
公开(公告)日：2022-01-13
申请号：US17293139
申请日：2019-11-08
申请人： ORANO MED
发明人： Julien Torgue , Rémy Dureau
摘要： A method for preparing one or more generators with a high radium-228 content from an aqueous solution comprising thorium-232 and radium-228. The generator(s) can be used, in particular, for producing thorium-228, from which radium-224, then lead-212 and bismuth-212 can be obtained. The method and the generator(s) that it can be used to prepare are therefore applicable, in particular, in the manufacture of radiopharmaceuticals made from lead-212 or bismuth-212, which can be used in nuclear medicine and, in particular, in targeted alpha radiotherapy for the treatment of cancers.
-
公开(公告)号：US10861615B2
公开(公告)日：2020-12-08
申请号：US15778397
申请日：2016-11-22
申请人： Orano Med
摘要： A process for producing a daughter radionuclide from a parent radionuclide includes a) loading the parent radionuclide on a first solid medium contained in a generator and onto which the parent radionuclide is retained and whereby the daughter radionuclide is formed by radioactive decay of the parent radionuclide; b) eluting this medium with a A0 solution so as to recover a A1 solution comprising the daughter radionuclide; c) optionally adjusting the pH of the A1 solution so as to obtain a A1′ solution, d) loading this A1 or A1′ solution onto the head of a second solid medium contained in a chromatography column; e) first washing said second solid medium with a A2 solution; f) second washing said second solid medium with a A2′ solution; g) eluting the daughter radionuclide with a A3 solution. The first washing step is conducted from head to tail of the column and the second washing step and the second eluting step are conducted from tail to head of the column.
-
公开(公告)号：US10020086B2
公开(公告)日：2018-07-10
申请号：US14402325
申请日：2013-05-23
申请人： Orano Med
CPC分类号： G21G1/0005 , A61K51/12 , C22B13/02 , C22B13/06 , C22C11/00 , G21G4/08 , G21G2001/0094
摘要： The invention relates to a method for preparing lead (212) for medical use. This method comprises the production of lead (212) by the decay of radium (224) in a generator comprising a solid medium to which the radium (224) is bound, followed by the extraction of the lead (212) from the generator in the form of an aqueous solution A1, characterized in that the lead (212) contained in the aqueous solution A1 is purified from the radiological and chemical impurities, also contained in said aqueous solution, by a liquid chromatography on a column. The invention also relates to an apparatus specially designed for automated implementation in a closed system of said method. It further relates to lead (212) produced by means of this method and this apparatus. Applications: manufacture of radiopharmaceuticals based on lead (212), useful in nuclear medicine for the treatment of cancers, particularly by a-radioimmunotherapy, or for medical imaging, in both humans and animals.
-
公开(公告)号：US12100528B2
公开(公告)日：2024-09-24
申请号：US17293139
申请日：2019-11-08
申请人： ORANO MED
发明人： Julien Torgue , Rémy Dureau
CPC分类号： G21G4/08 , B01D15/1871 , G21G1/0005
摘要： A method for preparing one or more generators with a high radium-228 content from an aqueous solution comprising thorium-232 and radium-228. The generator(s) can be used, in particular, for producing thorium-228, from which radium-224, then lead-212 and bismuth-212 can be obtained. The method and the generator(s) that it can be used to prepare are therefore applicable, in particular, in the manufacture of radiopharmaceuticals made from lead-212 or bismuth-212, which can be used in nuclear medicine and, in particular, in targeted alpha radiotherapy for the treatment of cancers.
-
公开(公告)号：US20230411033A1
公开(公告)日：2023-12-21
申请号：US18450074
申请日：2023-08-15
申请人： ORANO MED
发明人： Julien Torgue , Rémy Dureau
IPC分类号： G21G1/00
CPC分类号： G21G1/001 , G21G2001/0094 , G21G1/0005
摘要： A method for preparing one or more generators with a high radium-228 content from an aqueous solution comprising thorium-232 and radium-228. The generator(s) can be used, in particular, for producing thorium-228, from which radium-224, then lead-212 and bismuth-212 can be obtained. The method and the generator(s) so prepared are therefore applicable, in particular, in the manufacture of radiopharmaceuticals made from lead-212 or bismuth-212, which can be used in nuclear medicine and, in particular, in targeted alpha radiotherapy for the treatment of cancers.
-
8.发明公开公开(公告)号：US20230372552A1
公开(公告)日：2023-11-23
申请号：US18246706
申请日：2021-09-22
申请人： ORANO MED
发明人： Julien Torgue , Tania Stallons , Amy Wong , Amal Saidi
CPC分类号： A61K51/088 , A61P35/00
摘要： A conjugate or a pharmaceutically acceptable salt thereof, the conjugate being of formula: C-L-A, wherein C is a chelator, L is a linker covalently bound to the chelator and A is a Gastrin-releasing peptide receptor antagonist covalently bound to the linker, wherein: the chelator is of formula:
where the dotted line represents the covalent bond to the linker; the linker is of formula: -β-Ala-β-Ala-; and the Gastrin-releasing peptide receptor antagonist has the amino acid sequence: -DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2.-
公开(公告)号：US20230120220A1
公开(公告)日：2023-04-20
申请号：US17798879
申请日：2021-02-11
申请人： Orano Med
摘要： A process is for preparing a site-specific bioconjugated antibody of a formula (I): Ab-(Linker-Chelator)n (I). The Linker is an oligopeptide with an N-terminal end. The Chelator is a metal chelating agent. n is a Chelator-to antibody ratio (CAR), wherein 0
-
公开(公告)号：US20180350480A1
公开(公告)日：2018-12-06
申请号：US15778397
申请日：2016-11-22
申请人： Orano Med
CPC分类号： G21G1/0005 , G21G2001/0094
摘要： The present invention concerns a process for producing a daughter radionuclide from a parent radionuclide comprising the purification of the daughter radionuclide on a chromatography column, as well as the apparatus for carrying out such process.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.015 秒)
